MDT-AP-0395
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 54.96
- os_event
- false
- age_years
- 12
- sex
- M
- new_clusters
- C6
- umap1_2d
- 3.179294952
- umap2_2d
- 6.729445809
- umap1_3d
- 2.348706644
- umap2_3d
- -0.224778207
- umap3_3d
- -4.539045981
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.400
- DNA_REPAIR+0.310
- OXIDATIVE_PHOSPHORYLATION+0.280
- HEME_METABOLISM+0.130
- PEROXISOME+0.120
- ADIPOGENESIS+0.110
- MYC_TARGETS_V1+0.110
- UNFOLDED_PROTEIN_RESPONSE+0.080
- PI3K_AKT_MTOR_SIGNALING+0.070
- FATTY_ACID_METABOLISM+0.060
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.560
- ALLOGRAFT_REJECTION-0.520
- INTERFERON_ALPHA_RESPONSE-0.500
- INFLAMMATORY_RESPONSE-0.490
- INTERFERON_GAMMA_RESPONSE-0.490
- APICAL_SURFACE-0.460
- TNFA_SIGNALING_VIA_NFKB-0.460
- IL6_JAK_STAT3_SIGNALING-0.410
- ANGIOGENESIS-0.400
- IL2_STAT5_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3207 | Med | Medulloblastoma | 0.945 |
| 2 | BS_J8G4SH4Z | Med | Medulloblastoma | 0.931 |
| 3 | MDT-AP-0566 | Med | Medulloblastoma | 0.921 |
| 4 | SRR819999 | GTEX | — | 0.920 |
| 5 | SRR1407560 | GTEX | — | 0.911 |
| 6 | BS_K74PZET7 | Med | Medulloblastoma | 0.910 |
| 7 | SRR1387875 | GTEX | — | 0.909 |
| 8 | SRR1325665 | GTEX | — | 0.908 |
| 9 | SRR1348446 | GTEX | — | 0.908 |
| 10 | SRR656179 | GTEX | — | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.110 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |